Love him or hate him, one has to concede that Martin Shkreli is an exceptionally insightful person, having a knack for sniffing out the underlying trends, but impaired by a heavily skewed moral compass. Now, as the Dow Jones index does something it hasn't done since 1978, the infamous former pharma executive wants you to short hyped-up names, including Bitcoin, MicroStrategy, quantum computing stocks, and a cancer-focused biotech firm. Our readers would presumably recognize Martin Shkreli as the notorious C-suite executive who had jacked up the price of a life-saving drug, Daraprim, by 5,000 percent, winning widespread condemnation and an […]